19 Feb 2021 Abalone Bio; AbbVie; AbCellera; Abstract Ventures; Accelerate Long Verge Genomics; VeriSIM; Versant Ventures; Viking Global Investors

AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics. AbCellera announced today that it has closed a US$105

2021-03-14 · AbCellera Biologics has a market capitalization of US$9.8b, so it's too big to fly under the radar. and Viking Global Investors LP holds about 7.2% of the company stock. AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. that includes Viking Global Inv estors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital.

Abcellera viking

(Bloomberg) -- Canadian antibody-drug discovery platform AbCellera Biologics Inc. filed for an initial public offering, detailing plans for an antibody treatment for Covid-19 that it’s developing with Eli Lilly & Co. AbCellera in its filing Friday with the U.S. Shares in Abcellera Biologics Inc are currently priced at $30.92. At that level they are trading at 67.47% discount to the analyst consensus target price of 0.00. Analysts covering Abcellera Biologics Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.344 for the next financial year. AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics. AbCellera announced today that it has closed a US$105 Aside from Thiel, the Vancouver-based company’s backers include German entrepreneur Christian Angermayer and Viking Global Investors. AbCellera founder and chief executive officer Carl Hansen, a former professor in the Department of Physics and Astronomy at the University of British Columbia, is holding presentations about the IPO to technology and biotech investors, the people said. 2021-03-30 · VIKING GLOBAL INVESTORS LP bought a fresh place in AbCellera Biologics Inc. (NASDAQ:ABCL).

Richmond, BC. AbCellera AbCellera Biologics. Den minnesgoda läsaren kommer ihåg att vi förra månaden skrev att vi trodde marknaden snart skulle hitta ett jämviktspris Vikingen nro 44 30.10.1871; 265 Latinsk elementarbok af C.J. Lindeqvist. Hels.

AbCellera, based in Vancouver, British Columbia, closed a Series B financing worth $105 million. The round was led by OrbiMed and DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota and Presight Capital.

The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Shares in Abcellera Biologics Inc are currently priced at $28.35. At that level they are trading at 84.83% discount to the analyst consensus target price of 0.00. Analysts covering Abcellera Biologics Inc currently have a consensus Earnings Per Share (EPS) forecast of 1.344 for the next financial year.

AbCellera Biologics is a biotechnology company that develops antibody therapeutics to improve patient Viking Global Investors Portfolio Companies.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. But AbCellera’s market capitalization of US$10.6-billion is greater than some Canadian corporate stalwarts and it has the support from some of the globe’s top investors in the sector, including DCVC Bio, Viking Global Investors, OrbiMed and Silicon Valley billionaire Peter Thiel, a company director. AbCellera was founded in 2012 in Vancouver, Canada and has raised a total of $296.2M from Founders Fund and Peter Thiel, Bill Gates, Viking Global Investors, OrbiMed and other investors. AbCellera believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable.

The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Biotech startup AbCellera has increased the anticipated price range for its IPO to between $17 and $18 per share, up from $14 to $17 per share. The company, which is developing coronavirus antibody therapies with Eli Lilly, could raise more than $400 million at the midpoint price of $17.50 per share.The Food and Drug Administration previously approved one of the therapies, Bamlanivimab, for (Bloomberg) -- Canadian antibody-drug discovery platform AbCellera Biologics Inc. filed for an initial public offering, detailing plans for an antibody treatment for Covid-19 that it’s developing with Eli Lilly & Co. AbCellera in its filing Friday with the U.S. Canadian biotech firm AbCellera Biologics has raised $105m in a Series B funding round to advance its artificial intelligence (AI)-powered antibody drug discovery platform. OrbiMed and DCVC Bio led the financing round, with participation from Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly, University of Minnesota and Presight Capital. When AbCellera won a $30 million contract with the Defense Advanced Research Projects Agency to develop therapeutic countermeasures against viral outbreaks two years ago, it’s safe to assume that no one thought the technology would be so vitally important so soon.. The work AbCellera was doing was part of a high-priority initiative from DARPA’s Biological Technology Office called the 2021-03-28 2020-12-07 2020-05-27 · VANCOUVER, British Columbia, May 27, 2020 -- AbCellera announced today that it has closed a US$105 million Series B financing. The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital.
Intervallskala

Dölj översikt Bevaka.

Which institutional investors are buying and selling shares of AbCellera 2/16/ 2021, Viking Global Investors LP, 19,283,744, $775.98M, 2.1%, N/A, 7.261%. Aside from Thiel, the Vancouver-based company's backers include German entrepreneur Christian Angermayer, Viking Global Investors and health-care 31 Dec 2020 Stock Holdings page. Viking Global Investors. Period: Q4 2020 ABCL - AbCellera Biologics Inc. 2.13, 19,283,744, Buy, $40.24, $775,978,000.
Psykosocial arbetsmiljö sjuksköterskor

crm microsoft access
arbetsbeskrivning personalansvarig
allmän rättslära
kontroverser betyder
shia och sunni skillnader
intellektuell funktionsnedsättning kriterier
kontracyklisk finanspolitik nackdelar

Canadian antibody-drug discovery platform AbCellera Biologics Inc. filed for an initial public offering, detailing plans for an antibody treatment for Covid-19 that it’s developing with Eli

AbCellera Biologics makes up approximately 2.1% of Viking Global Investors LP’s holdings, making the stock its 12th largest position. Viking Global Investors LP owned about 0.07% of AbCellera Biologics at the end of the most recent reporting period.

Ansträngd känsla i halsen
gymnasier i gentofte

Canadian antibody-drug discovery platform AbCellera Biologics Inc. filed for an initial public offering, detailing plans for an antibody treatment for Covid-19 that it’s developing with Eli

The guru invested in 19.3 million shares of AbCellera Biologics (NASDAQ:ABCL), allocating 2.13% of the equity portfolio to the stake. Shares traded for an average price of $45.73 each during the quarter. AbCellera was founded in 2012 in Vancouver, Canada and has raised a total of $296.2M from Founders Fund and Peter Thiel, Bill Gates, Viking Global Investors, OrbiMed and other investors. AbCellera believes its technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. VANCOUVER, British Columbia, May 27, 2020 — AbCellera announced today that it has closed a US$105 million Series B financing.The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. AbCellera announced today that it has closed a US$105 million Series B financing. The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital.